山东新华制药股份(00719)获缬沙坦胶囊药品注册证书

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received the drug registration certificate for Valsartan capsules from the National Medical Products Administration, which is expected to enhance the company's product portfolio for cardiovascular disease treatment and improve its overall competitiveness [1]. Group 1 - The drug registration certificate for Valsartan capsules was approved and issued on December 2025 [1]. - The approval of Valsartan capsules will enrich the company's product line for treating cardiovascular diseases [1]. - This development is anticipated to strengthen the company's comprehensive competitiveness in the pharmaceutical industry [1].